{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,2]],"date-time":"2026-11-02T23:00:14Z","timestamp":1793660414731,"version":"4.5.1"},"reference-count":43,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2021,11,7]],"date-time":"2021-11-07T00:00:00Z","timestamp":1636243200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2021,11,7]],"date-time":"2021-11-07T00:00:00Z","timestamp":1636243200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Cancer"],"published-print":{"date-parts":[[2021,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>Virtually all metastatic patients with metastatic melanoma who progress after initial treatment with PD-1 or CTLA-4 directed antibodies will die of their disease. Salvage options are urgently needed. It is theoretically attractive to combine immunotherapy with targeted agents in progressing patients with BRAF mutation positive melanoma, but the toxicity of combined treatment has proven challenging.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>We performed a retrospective analysis of our patient database and identified 23 patients who progressed on initial checkpoint inhibitor treatment, who subsequently had cautious addition of BRAF\u00b1MEK inhibitor therapy to continued PD-1 antibody treatment.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>We found an objective response rate of 55% in second line therapy, with a median progression-free survival of 33.4\u2009months and median overall survival of 34.1\u2009months, with 40% of patients in unmaintained remission at over 3\u2009years. Ten of 12 responding patients were able to discont<jats:bold>i<\/jats:bold>nue all therapy and continue in unmaintained remission. Toxicity of this approach was generally manageable (21.7% grade 3\u20135 toxicity). There was 1 early sudden death for unknown reasons in a responding patient.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Discussion<\/jats:title>\n                <jats:p>Our results suggest that 2nd line therapy with PD-1 inhibitors plus BRAF\u00b1MEK inhibitors has substantial activity and manageable toxicity. This treatment can induce additional durable complete responses in patients who have progressed on initial immunotherapy. These results suggest further evaluation be performed of sequential PD-1 antibody treatment with cautious addition of targeted therapy in appropriate patients.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s12885-021-08906-1","type":"journal-article","created":{"date-parts":[[2021,11,7]],"date-time":"2021-11-07T19:02:40Z","timestamp":1636311760000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":11,"title":["Cautious addition of targeted therapy to PD-1 inhibitors after initial progression of BRAF mutant metastatic melanoma on checkpoint inhibitor therapy"],"prefix":"10.1186","volume":"21","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0713-914X","authenticated-orcid":false,"given":"Wolfram","family":"Samlowski","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Camille","family":"Adajar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,11,7]]},"reference":[{"issue":"1","key":"8906_CR1","doi-asserted-by":"publisher","first-page":"7","DOI":"10.3322\/caac.21590","volume":"70","author":"RL Siegel","year":"2020","unstructured":"Siegel RL, Miller KD, Jemal A. Cancer statistics, 2020. CA Cancer J Clin. 2020;70(1):7\u201330. https:\/\/doi.org\/10.3322\/caac.21590.","journal-title":"CA Cancer J Clin"},{"issue":"4","key":"8906_CR2","doi-asserted-by":"publisher","first-page":"465","DOI":"10.3390\/cancers11040465","volume":"11","author":"M Kunz","year":"2019","unstructured":"Kunz M, Vera J. Modelling of protein kinase signaling pathways in melanoma and other cancers. Cancers (Basel). 2019;11(4):465. https:\/\/doi.org\/10.3390\/cancers11040465.","journal-title":"Cancers (Basel)"},{"issue":"21","key":"8906_CR3","doi-asserted-by":"publisher","first-page":"4902","DOI":"10.1002\/cncr.25261","volume":"116","author":"KT Flaherty","year":"2010","unstructured":"Flaherty KT, McArthur G. BRAF, a target in melanoma: implications for solid tumor drug development. Cancer. 2010;116(21):4902\u201313. https:\/\/doi.org\/10.1002\/cncr.25261.","journal-title":"Cancer"},{"issue":"1","key":"8906_CR4","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.immuni.2013.07.012","volume":"39","author":"DS Chen","year":"2013","unstructured":"Chen DS, Mellman I. Oncology meets immunology: the cancer-immunity cycle. Immunity. 2013;39(1):1\u201310. https:\/\/doi.org\/10.1016\/j.immuni.2013.07.012.","journal-title":"Immunity"},{"issue":"4","key":"8906_CR5","doi-asserted-by":"publisher","first-page":"527","DOI":"10.1200\/JCO.2007.12.7837","volume":"26","author":"EL Korn","year":"2008","unstructured":"Korn EL, Liu PY, Lee SJ, Chapman JA, Niedzwiecki D, Suman VJ, et al. Meta-analysis of phase II cooperative group trials in metastatic stage IV melanoma to determine progression-free and overall survival benchmarks for future phase II trials. J Clin Oncol. 2008;26(4):527\u201334. https:\/\/doi.org\/10.1200\/JCO.2007.12.7837.","journal-title":"J Clin Oncol"},{"issue":"16","key":"8906_CR6","doi-asserted-by":"publisher","first-page":"1535","DOI":"10.1056\/NEJMoa1910836","volume":"381","author":"J Larkin","year":"2019","unstructured":"Larkin J, Chiarion-Sileni V, Gonzalez R, Grob JJ, Rutkowski P, Lao CD, et al. Five-year survival with combined Nivolumab and Ipilimumab in advanced melanoma. N Engl J Med. 2019;381(16):1535\u201346. https:\/\/doi.org\/10.1056\/NEJMoa1910836.","journal-title":"N Engl J Med"},{"issue":"7","key":"8906_CR7","doi-asserted-by":"publisher","first-page":"626","DOI":"10.1056\/NEJMoa1904059","volume":"381","author":"C Robert","year":"2019","unstructured":"Robert C, Grob JJ, Stroyakovskiy D, Karaszewska B, Hauschild A, Levchenko E, et al. Five-year outcomes with Dabrafenib plus Trametinib in metastatic melanoma. N Engl J Med. 2019;381(7):626\u201336. https:\/\/doi.org\/10.1056\/NEJMoa1904059.","journal-title":"N Engl J Med"},{"issue":"1","key":"8906_CR8","doi-asserted-by":"publisher","first-page":"665","DOI":"10.1186\/s12885-019-5864-1","volume":"19","author":"PM Lokhandwala","year":"2019","unstructured":"Lokhandwala PM, Tseng LH, Rodriguez E, Zheng G, Pallavajjalla A, Gocke CD, et al. Clinical mutational profiling and categorization of BRAF mutations in melanomas using next generation sequencing. BMC Cancer. 2019;19(1):665. https:\/\/doi.org\/10.1186\/s12885-019-5864-1.","journal-title":"BMC Cancer"},{"issue":"6","key":"8906_CR9","doi-asserted-by":"publisher","first-page":"900","DOI":"10.1007\/s12094-019-02207-7","volume":"22","author":"F Consoli","year":"2019","unstructured":"Consoli F, Bersanelli M, Perego G, Grisanti S, Merelli B, Berruti A, et al. Network indirect comparison of 3 BRAF + MEK inhibitors for the treatment of advanced BRAF mutated melanoma. Clin Transl Oncol. 2019;22(6):900\u20137. https:\/\/doi.org\/10.1007\/s12094-019-02207-7.","journal-title":"Clin Transl Oncol"},{"issue":"14","key":"8906_CR10","doi-asserted-by":"publisher","first-page":"1628","DOI":"10.1200\/JCO.2011.39.1938","volume":"30","author":"GA McArthur","year":"2012","unstructured":"McArthur GA, Puzanov I, Amaravadi R, Ribas A, Chapman P, Kim KB, et al. Marked, homogeneous, and early [18F]fluorodeoxyglucose-positron emission tomography responses to vemurafenib in BRAF-mutant advanced melanoma. J Clin Oncol. 2012;30(14):1628\u201334. https:\/\/doi.org\/10.1200\/JCO.2011.39.1938.","journal-title":"J Clin Oncol"},{"issue":"7","key":"8906_CR11","doi-asserted-by":"publisher","first-page":"1631","DOI":"10.1093\/annonc\/mdx176","volume":"28","author":"GV Long","year":"2017","unstructured":"Long GV, Flaherty KT, Stroyakovskiy D, Gogas H, Levchenko E, de Braud F, et al. Dabrafenib plus trametinib versus dabrafenib monotherapy in patients with metastatic BRAF V600E\/K-mutant melanoma: long-term survival and safety analysis of a phase 3 study. Ann Oncol. 2017;28(7):1631\u20139. https:\/\/doi.org\/10.1093\/annonc\/mdx176.","journal-title":"Ann Oncol"},{"issue":"9","key":"8906_CR12","doi-asserted-by":"publisher","first-page":"1069","DOI":"10.1158\/2159-8290.CD-18-0367","volume":"8","author":"SC Wei","year":"2018","unstructured":"Wei SC, Duffy CR, Allison JP. Fundamental mechanisms of immune checkpoint blockade therapy. Cancer Discov. 2018;8(9):1069\u201386. https:\/\/doi.org\/10.1158\/2159-8290.CD-18-0367.","journal-title":"Cancer Discov"},{"issue":"7637","key":"8906_CR13","doi-asserted-by":"publisher","first-page":"321","DOI":"10.1038\/nature21349","volume":"541","author":"DS Chen","year":"2017","unstructured":"Chen DS, Mellman I. Elements of cancer immunity and the cancer-immune set point. Nature. 2017;541(7637):321\u201330. https:\/\/doi.org\/10.1038\/nature21349.","journal-title":"Nature"},{"issue":"1","key":"8906_CR14","doi-asserted-by":"publisher","first-page":"305","DOI":"10.1186\/s40425-019-0770-2","volume":"7","author":"S Chen","year":"2019","unstructured":"Chen S, Crabill GA, Pritchard TS, McMiller TL, Wei P, Pardoll DM, et al. Mechanisms regulating PD-L1 expression on tumor and immune cells. J Immunother Cancer. 2019;7(1):305. https:\/\/doi.org\/10.1186\/s40425-019-0770-2.","journal-title":"J Immunother Cancer"},{"issue":"11","key":"8906_CR15","doi-asserted-by":"publisher","first-page":"1113","DOI":"10.1001\/jama.2015.11929","volume":"314","author":"JP Allison","year":"2015","unstructured":"Allison JP. Immune checkpoint blockade in Cancer therapy: the 2015 Lasker-DeBakey clinical medical research award. JAMA. 2015;314(11):1113\u20134. https:\/\/doi.org\/10.1001\/jama.2015.11929.","journal-title":"JAMA"},{"issue":"4","key":"8906_CR16","doi-asserted-by":"publisher","first-page":"582","DOI":"10.1093\/annonc\/mdz011","volume":"30","author":"O Hamid","year":"2019","unstructured":"Hamid O, Robert C, Daud A, Hodi FS, Hwu WJ, Kefford R, et al. Five-year survival outcomes for patients with advanced melanoma treated with pembrolizumab in KEYNOTE-001. Ann Oncol. 2019;30(4):582\u20138. https:\/\/doi.org\/10.1093\/annonc\/mdz011.","journal-title":"Ann Oncol"},{"key":"8906_CR17","doi-asserted-by":"publisher","first-page":"990","DOI":"10.3389\/fimmu.2019.00990","volume":"10","author":"C Yu","year":"2019","unstructured":"Yu C, Liu X, Yang J, Zhang M, Jin H, Ma X, et al. Combination of immunotherapy with targeted therapy: theory and practice in metastatic melanoma. Front Immunol. 2019;10:990. https:\/\/doi.org\/10.3389\/fimmu.2019.00990.","journal-title":"Front Immunol"},{"key":"8906_CR18","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1016\/j.phrs.2018.08.019","volume":"136","author":"M Kuske","year":"2018","unstructured":"Kuske M, Westphal D, Wehner R, Schmitz M, Beissert S, Praetorius C, et al. Immunomodulatory effects of BRAF and MEK inhibitors: implications for melanoma therapy. Pharmacol Res. 2018;136:151\u20139. https:\/\/doi.org\/10.1016\/j.phrs.2018.08.019.","journal-title":"Pharmacol Res"},{"issue":"9","key":"8906_CR19","doi-asserted-by":"publisher","first-page":"2783","DOI":"10.1158\/1078-0432.CCR-18-2725","volume":"25","author":"C Atay","year":"2019","unstructured":"Atay C, Kwak T, Lavilla-Alonso S, Donthireddy L, Richards A, Moberg V, et al. BRAF targeting sensitizes resistant melanoma to cytotoxic T cells. Clin Cancer Res. 2019;25(9):2783\u201394. https:\/\/doi.org\/10.1158\/1078-0432.CCR-18-2725.","journal-title":"Clin Cancer Res"},{"issue":"14","key":"8906_CR20","doi-asserted-by":"publisher","first-page":"3377","DOI":"10.1158\/1078-0432.CCR-17-1914","volume":"24","author":"M Sanlorenzo","year":"2018","unstructured":"Sanlorenzo M, Vujic I, Floris A, Novelli M, Gammaitoni L, Giraudo L, et al. BRAF and MEK inhibitors increase PD-1-positive melanoma cells leading to a potential lymphocyte-independent synergism with anti-PD-1 antibody. Clin Cancer Res. 2018;24(14):3377\u201385. https:\/\/doi.org\/10.1158\/1078-0432.CCR-17-1914.","journal-title":"Clin Cancer Res"},{"issue":"1","key":"8906_CR21","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1186\/s40425-018-0475-y","volume":"7","author":"AR Naqash","year":"2019","unstructured":"Naqash AR, File DM, Ziemer CM, Whang YE, Landman P, Googe PB, et al. Cutaneous adverse reactions in B-RAF positive metastatic melanoma following sequential treatment with B-RAF\/MEK inhibitors and immune checkpoint blockade or vice versa. A single-institutional case-series. J Immunother Cancer. 2019;7(1):4. https:\/\/doi.org\/10.1186\/s40425-018-0475-y.","journal-title":"J Immunother Cancer"},{"issue":"4","key":"8906_CR22","doi-asserted-by":"publisher","first-page":"306","DOI":"10.1097\/CCO.0000000000000295","volume":"28","author":"HR Kourie","year":"2016","unstructured":"Kourie HR, Klastersky JA. Side-effects of checkpoint inhibitor-based combination therapy. Curr Opin Oncol. 2016;28(4):306\u201313. https:\/\/doi.org\/10.1097\/CCO.0000000000000295.","journal-title":"Curr Opin Oncol"},{"issue":"5","key":"8906_CR23","doi-asserted-by":"publisher","first-page":"1225","DOI":"10.1158\/1078-0432.CCR-12-1630","volume":"19","author":"DT Frederick","year":"2013","unstructured":"Frederick DT, Piris A, Cogdill AP, Cooper ZA, Lezcano C, Ferrone CR, et al. BRAF inhibition is associated with enhanced melanoma antigen expression and a more favorable tumor microenvironment in patients with metastatic melanoma. Clin Cancer Res. 2013;19(5):1225\u201331. https:\/\/doi.org\/10.1158\/1078-0432.CCR-12-1630.","journal-title":"Clin Cancer Res"},{"issue":"1","key":"8906_CR24","doi-asserted-by":"publisher","first-page":"289","DOI":"10.3390\/ijms19010289","volume":"19","author":"J Dorrie","year":"2018","unstructured":"Dorrie J, Babalija L, Hoyer S, Gerer KF, Schuler G, Heinzerling L, et al. BRAF and MEK inhibitors influence the function of reprogrammed T cells: consequences for adoptive T-cell therapy. Int J Mol Sci. 2018;19(1):289. https:\/\/doi.org\/10.3390\/ijms19010289.","journal-title":"Int J Mol Sci"},{"issue":"6","key":"8906_CR25","doi-asserted-by":"publisher","first-page":"e29126","DOI":"10.4161\/onci.29126","volume":"3","author":"PC Ho","year":"2014","unstructured":"Ho PC, Kaech SM. BRAF-targeted therapy alters the functions of intratumoral CD4(+) T cells to inhibit melanoma progression. Oncoimmunology. 2014;3(6):e29126. https:\/\/doi.org\/10.4161\/onci.29126.","journal-title":"Oncoimmunology"},{"issue":"1","key":"8906_CR26","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1016\/j.molonc.2014.07.014","volume":"9","author":"S Tomei","year":"2015","unstructured":"Tomei S, Bedognetti D, De Giorgi V, Sommariva M, Civini S, Reinboth J, et al. The immune-related role of BRAF in melanoma. Mol Oncol. 2015;9(1):93\u2013104. https:\/\/doi.org\/10.1016\/j.molonc.2014.07.014.","journal-title":"Mol Oncol"},{"issue":"282","key":"8906_CR27","doi-asserted-by":"publisher","first-page":"457","DOI":"10.1080\/01621459.1958.10501452","volume":"53","author":"EL Kaplan","year":"1958","unstructured":"Kaplan EL, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc. 1958;53(282):457\u201381. https:\/\/doi.org\/10.1080\/01621459.1958.10501452.","journal-title":"J Am Stat Assoc"},{"issue":"4","key":"8906_CR28","doi-asserted-by":"publisher","first-page":"244","DOI":"10.4103\/sajc.sajc_389_18","volume":"8","author":"W Abbas","year":"2019","unstructured":"Abbas W, Rao RR, Popli S. Hyperprogression after immunotherapy. South Asian J Cancer. 2019;8(4):244\u20136. https:\/\/doi.org\/10.4103\/sajc.sajc_389_18.","journal-title":"South Asian J Cancer"},{"issue":"17","key":"8906_CR29","doi-asserted-by":"publisher","first-page":"1668","DOI":"10.1200\/JCO.2017.75.6270","volume":"36","author":"C Robert","year":"2018","unstructured":"Robert C, Ribas A, Hamid O, Daud A, Wolchok JD, Joshua AM, et al. Durable complete response after discontinuation of Pembrolizumab in patients with metastatic melanoma. J Clin Oncol. 2018;36(17):1668\u201374. https:\/\/doi.org\/10.1200\/JCO.2017.75.6270.","journal-title":"J Clin Oncol"},{"issue":"8","key":"8906_CR30","doi-asserted-by":"publisher","first-page":"1256","DOI":"10.1001\/jamaoncol.2020.2288","volume":"6","author":"I Puzanov","year":"2020","unstructured":"Puzanov I, Ribas A, Robert C, Schachter J, Nyakas M, Daud A, et al. Association of BRAF V600E\/K mutation status and prior BRAF\/MEK inhibition with Pembrolizumab outcomes in advanced melanoma: pooled analysis of 3 clinical trials. JAMA Oncol. 2020;6(8):1256\u201364. https:\/\/doi.org\/10.1001\/jamaoncol.2020.2288.","journal-title":"JAMA Oncol"},{"issue":"21","key":"8906_CR31","doi-asserted-by":"publisher","first-page":"2248","DOI":"10.1200\/JCO.2013.52.1377","volume":"32","author":"S Hu-Lieskovan","year":"2014","unstructured":"Hu-Lieskovan S, Robert L, Homet Moreno B, Ribas A. Combining targeted therapy with immunotherapy in BRAF-mutant melanoma: promise and challenges. J Clin Oncol. 2014;32(21):2248\u201354. https:\/\/doi.org\/10.1200\/JCO.2013.52.1377.","journal-title":"J Clin Oncol"},{"issue":"10","key":"8906_CR32","doi-asserted-by":"publisher","first-page":"1557","DOI":"10.1038\/s41591-020-1082-2","volume":"26","author":"R Dummer","year":"2020","unstructured":"Dummer R, Lebbe C, Atkinson V, Mandala M, Nathan PD, Arance A, et al. Combined PD-1, BRAF and MEK inhibition in advanced BRAF-mutant melanoma: safety run-in and biomarker cohorts of COMBI-i. Nat Med. 2020;26(10):1557\u201363. https:\/\/doi.org\/10.1038\/s41591-020-1082-2.","journal-title":"Nat Med"},{"issue":"10240","key":"8906_CR33","doi-asserted-by":"publisher","first-page":"1835","DOI":"10.1016\/S0140-6736(20)30934-X","volume":"395","author":"R Gutzmer","year":"2020","unstructured":"Gutzmer R, Stroyakovskiy D, Gogas H, Robert C, Lewis K, Protsenko S, et al. Atezolizumab, vemurafenib, and cobimetinib as first-line treatment for unresectable advanced BRAF(V600) mutation-positive melanoma (IMspire150): primary analysis of the randomised, double-blind, placebo-controlled, phase 3 trial. Lancet. 2020;395(10240):1835\u201344. https:\/\/doi.org\/10.1016\/S0140-6736(20)30934-X.","journal-title":"Lancet"},{"issue":"2","key":"8906_CR34","doi-asserted-by":"publisher","first-page":"e001806","DOI":"10.1136\/jitc-2020-001806","volume":"8","author":"PF Ferrucci","year":"2020","unstructured":"Ferrucci PF, Di Giacomo AM, Del Vecchio M, Atkinson V, Schmidt H, Schachter J, et al. KEYNOTE-022 part 3: a randomized, double-blind, phase 2 study of pembrolizumab, dabrafenib, and trametinib in BRAF-mutant melanoma. J Immunother Cancer. 2020;8(2):e001806. https:\/\/doi.org\/10.1136\/jitc-2020-001806.","journal-title":"J Immunother Cancer"},{"issue":"suppl_4","key":"8906_CR35","first-page":"S1142","volume":"31","author":"P Nathan","year":"2020","unstructured":"Nathan P, Dummer R, Long GV, Ascierto PA, Tawbi HA, Robert C, et al. Spartalizumab plus dabrafenib and trametinib in patients with previously untreated BRAF V600-mutant unresectable or metastatic melanoma: Results from the randomized part 3 of the phase III COMBI-i trial. Ann Oncol. 2020;31(suppl_4):S1142\u2013215.","journal-title":"Ann Oncol"},{"issue":"3","key":"8906_CR36","doi-asserted-by":"publisher","first-page":"293","DOI":"10.2217\/bmm.11.37","volume":"5","author":"M Cronin","year":"2011","unstructured":"Cronin M, Ross JS. Comprehensive next-generation cancer genome sequencing in the era of targeted therapy and personalized oncology. Biomark Med. 2011;5(3):293\u2013305. https:\/\/doi.org\/10.2217\/bmm.11.37.","journal-title":"Biomark Med"},{"issue":"18","key":"8906_CR37","doi-asserted-by":"publisher","first-page":"7637","DOI":"10.1002\/cam4.2625","volume":"8","author":"JC Moser","year":"2019","unstructured":"Moser JC, Chen D, Hu-Lieskovan S, Grossmann KF, Patel S, Colonna SV, et al. Real-world survival of patients with advanced BRAF V600 mutated melanoma treated with front-line BRAF\/MEK inhibitors, anti-PD-1 antibodies, or nivolumab\/ipilimumab. Cancer Med. 2019;8(18):7637\u201343. https:\/\/doi.org\/10.1002\/cam4.2625.","journal-title":"Cancer Med"},{"issue":"2","key":"8906_CR38","doi-asserted-by":"publisher","first-page":"358","DOI":"10.1111\/pcmr.12831","volume":"33","author":"R Mason","year":"2020","unstructured":"Mason R, Dearden HC, Nguyen B, Soon JA, Smith JL, Randhawa M, et al. Combined ipilimumab and nivolumab first-line and after BRAF-targeted therapy in advanced melanoma. Pigment Cell Melanoma Res. 2020;33(2):358\u201365. https:\/\/doi.org\/10.1111\/pcmr.12831.","journal-title":"Pigment Cell Melanoma Res"},{"issue":"14","key":"8906_CR39","doi-asserted-by":"publisher","first-page":"1241","DOI":"10.2217\/imt-2018-0085","volume":"10","author":"A Tarhini","year":"2018","unstructured":"Tarhini A, Benedict A, McDermott D, Rao S, Ambavane A, Gupte-Singh K, et al. Sequential treatment approaches in the management of BRAF wild-type advanced melanoma: a cost-effectiveness analysis. Immunotherapy. 2018;10(14):1241\u201352. https:\/\/doi.org\/10.2217\/imt-2018-0085.","journal-title":"Immunotherapy"},{"issue":"10","key":"8906_CR40","doi-asserted-by":"publisher","first-page":"1020","DOI":"10.1200\/JCO.2013.53.0105","volume":"32","author":"SL Topalian","year":"2014","unstructured":"Topalian SL, Sznol M, McDermott DF, Kluger HM, Carvajal RD, Sharfman WH, et al. Survival, durable tumor remission, and long-term safety in patients with advanced melanoma receiving nivolumab. J Clin Oncol. 2014;32(10):1020\u201330. https:\/\/doi.org\/10.1200\/JCO.2013.53.0105.","journal-title":"J Clin Oncol"},{"issue":"2","key":"8906_CR41","doi-asserted-by":"publisher","first-page":"134","DOI":"10.1056\/NEJMoa1305133","volume":"369","author":"O Hamid","year":"2013","unstructured":"Hamid O, Robert C, Daud A, Hodi FS, Hwu WJ, Kefford R, et al. Safety and tumor responses with lambrolizumab (anti-PD-1) in melanoma. N Engl J Med. 2013;369(2):134\u201344. https:\/\/doi.org\/10.1056\/NEJMoa1305133.","journal-title":"N Engl J Med"},{"issue":"9829","key":"8906_CR42","doi-asserted-by":"publisher","first-page":"1893","DOI":"10.1016\/S0140-6736(12)60398-5","volume":"379","author":"GS Falchook","year":"2012","unstructured":"Falchook GS, Long GV, Kurzrock R, Kim KB, Arkenau TH, Brown MP, et al. Dabrafenib in patients with melanoma, untreated brain metastases, and other solid tumours: a phase 1 dose-escalation trial. Lancet. 2012;379(9829):1893\u2013901. https:\/\/doi.org\/10.1016\/S0140-6736(12)60398-5.","journal-title":"Lancet"},{"issue":"5","key":"8906_CR43","doi-asserted-by":"publisher","first-page":"1069","DOI":"10.1016\/j.ijrobp.2017.03.030","volume":"98","author":"PW Sperduto","year":"2017","unstructured":"Sperduto PW, Jiang W, Brown PD, Braunstein S, Sneed P, Wattson DA, et al. The prognostic value of BRAF, C-KIT, and NRAS mutations in melanoma patients with brain metastases. Int J Radiat Oncol Biol Phys. 2017;98(5):1069\u201377. https:\/\/doi.org\/10.1016\/j.ijrobp.2017.03.030.","journal-title":"Int J Radiat Oncol Biol Phys"}],"container-title":["BMC Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-021-08906-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12885-021-08906-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-021-08906-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,11,7]],"date-time":"2021-11-07T19:03:51Z","timestamp":1636311831000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmccancer.biomedcentral.com\/articles\/10.1186\/s12885-021-08906-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,11,7]]},"references-count":43,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2021,12]]}},"alternative-id":["8906"],"URL":"https:\/\/doi.org\/10.1186\/s12885-021-08906-1","relation":{},"ISSN":["1471-2407"],"issn-type":[{"value":"1471-2407","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,11,7]]},"assertion":[{"value":"28 February 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 October 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 November 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This retrospective data analysis was reviewed by the Western IRB and was judged to be exempt from full board review. Thus individual patient consent is not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"Neither of the authors reported any relevant conflicts of interest.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"1187"}}